About
Before ANI he was Chief Executive Officer of the India Rx Business at Cipla from April 2017 to April 2020, and he also served as CEO of Cipla USA from April 2017 to April 2020 and of InvaGen, a Cipla subsidiary, from April 2016 to April 2020. Earlier he worked as an Associate Partner at McKinsey & Company and as an engineer at Medtronic. He holds a B.S. in Electrical Engineering from the Georgia Institute of Technology and an M.B.A. from the Wharton School at the University of Pennsylvania. Other pharmaceutical leaders with pages on Whoo include David Ricks and Albert Bourla.
Whoo compiled this page from public sources: ANI Pharmaceuticals 2026 proxy statement (SEC), ANI Pharmaceuticals Form 10-K (SEC), ANI Pharmaceuticals Form 10-Q, September 2026 (SEC). It is not affiliated with or endorsed by Nikhil Lalwani. Are you Nikhil Lalwani? Claim this page, or write to [email protected] to correct or remove it. Last updated: 2026-11-18.
Want a page like this? Create yours from your résumé.
Experience
President and Chief Executive Officer — ANI Pharmaceuticals
September 2020 – Present | Princeton, New Jersey
Chief Executive Officer, India Rx Business — Cipla
April 2017 – April 2020
Chief Executive Officer — Cipla USA and InvaGen
Cipla USA: April 2017 – April 2020; InvaGen: April 2016 – April 2020